Teva Pharmaceutical’s Promising R&D Pipeline and Strategic Growth Prospects
TipRanks (Fri, 17-May 5:16 AM ET)
Larry Robbins' Glenview Capital takes in Broadcom, exits Intel among Q1 moves
Seeking Alpha News (Thu, 16-May 11:01 AM ET)
Teva Pharmaceutical Welcomes New EVP Amid Leadership Changes
TipRanks (Wed, 15-May 8:42 AM ET)
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
Business Wire (Wed, 15-May 8:15 AM ET)
TipRanks (Mon, 13-May 6:51 AM ET)
Benzinga (Sun, 12-May 1:33 PM ET)
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
Business Wire (Wed, 8-May 7:00 AM ET)
Business Wire (Wed, 8-May 6:30 AM ET)
Teva to Present at the 2024 Bank of America Healthcare Conference
Business Wire (Thu, 2-May 6:30 PM ET)
Teva's 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
Business Wire (Thu, 2-May 8:30 AM ET)
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Teva Pharmaceutical Industries Limited American Depositary Shares trades on the NYSE stock market under the symbol TEVA.
As of May 17, 2024, TEVA stock price declined to $16.24 with 5,023,014 million shares trading.
TEVA has a beta of 0.77, meaning it tends to be less sensitive to market movements. TEVA has a correlation of 0.07 to the broad based SPY ETF.
TEVA has a market cap of $18.39 billion. This is considered a Large Cap stock.
Last quarter Teva Pharmaceutical Industries Limited American Depositary Shares reported $4 billion in Revenue and $.48 earnings per share. This beat revenue expectation by $89 million and missed earnings estimates by -$.03.
In the last 3 years, TEVA stock traded as high as $17.13 and as low as $6.78.
The top ETF exchange traded funds that TEVA belongs to (by Net Assets): RAYD, IEFA, EFA, EFV, IXUS.
TEVA has outperformed the market in the last year with a price return of +99.8% while the SPY ETF gained +30.5%. TEVA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +24.7% and +15.3%, respectively, while the SPY returned +6.2% and +4.7%, respectively.
TEVA support price is $15.96 and resistance is $16.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TEVA stock will trade within this expected range on the day.